Scientific Understanding to Mitigate Risks in DPI Development:
New Publication by Dr. Kyrre Thalberg
In the development of Dry Powder Inhalers (DPIs), the path from formulation to regulatory approval is often fraught with technical challenges. One common cause of costly project delays is a lack of fundamental understanding of how drug particles interact with their carriers.
Our Senior Advisor, Dr. Kyrre Thalberg, has as lead author recently published a scientific article in the Journal of Drug Delivery Science and Technology:
The effect of carrier particle size on the performance of adhesive mixtures for inhalation
How this research helps your project:
For our partners, the gain from Dr Thalberg’s expertise translates directly into a competitive business advantage, such as:
- Selecting the best carrier particles and mixing method: Enable prediction of stability and delivery issues before they reach the critical path of your project timeline.
- Minimize “Trial-and-Error”: Rather than relying on time-consuming re-testing, we base our advisory on proven science, ensuring a faster “Proof-of-Concept.”
At Emmace, we do not just deliver raw data, we deliver the understanding needed to advancing projects. With “hundreds of years of combined experience,” we do our best to keep your project on track and within budget.
Read the full article here.
Are you looking to optimize your DPI formulation and avoid unnecessary delays?
Contact Dr Kyrre Thalberg for a strategic consultation.
kyrre(a)emmace.se